ACT-1004-1239 | CXCR7 antagonist | Probechem Biochemicals

Chemical Structure : ACT-1004-1239

CAS No.: 2178049-58-4

加入收藏

ACT-1004-1239 (ACT1004-1239)

货号: PC-72634Not For Human Use, Lab Use Only.

ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with IC50 of 3.2 nM (hCXCR7).

规格	价格	库存
2 mg	￥2980	In stock
5 mg	￥4980	In stock
10 mg	￥7580	In stock
25 mg		Get quote
100 mg		Get quote

获取报价单

* 请选择数量再加入购物车

or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

生物&药学活性

ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with IC50 of 3.2 nM (hCXCR7).
ACT-1004-1239 also shows similar potency against rat, mouse and dog CXCR (IC50=2-3 nM), shows high selectivity in a panel of 87 enzymatic and radioligand binding assays (CXCR4, IC50>10 uM).
ACT-1004-1239 is a potent insurmountable CXCR7 antagonist against both CXCL11 and CXCL12, shows a dose-dependent increase of CXCL12 plasma concentration in mice.

物理化学性质&存储条件

分子量	522.557
分子式	C27H28F2N6O3
外观性状	Solid
CAS No.
储存条件	固体粉末 -20°C 12 个月; 4°C 6 个月	配置液 -80°C 6 个月; -20°C 6 个月
Shipping
Solubility	10 mM in DMSO
Chemical Name/SMILES	3-Piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]amino]-N-[1-(2-pyrimidinyl)cyclopropyl]-, (3S,4S)-

参考文献

1. Sylvia Richard-Bildstein, et al. J Med Chem. 2020 Dec 24;63(24):15864-15882.

2. Huynh C, et al. Clin Pharmacol Ther. 2021 Jun;109(6):1648-1659.

3. Huynh C, et al. Biomed Pharmacother. 2021 Dec;144:112363.

ACT-1004-1239 (ACT1004-1239)

生物&药学活性

物理化学性质&存储条件

参考文献

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

询单

ACT-1004-1239 (ACT1004-1239)

生物&药学活性

物理化学性质&存储条件

参考文献

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

询单

Get Quotation Now

* Indicates a Required FieldYour information is safe with us.